Examines Darbepoetin for Neurodevelopment in Preterm Infants
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on September 10th, 2025
|
Preterm infants face a markedly higher risk of neurodevelopmental complications. Previous research has suggested that stimulating red blood cell production with erythropoietin may have neuroprotective effects. To further investigate this potential, a study recently published in the Journal of American Medical Association evaluated whether darbepoetin could improve neurodevelopmental outcomes in preterm infants.
The randomized clinical trial enrolled 650 infants with a mean gestational age of 26.2 weeks. Within 36 hours of birth, participants were assigned to receive either a placebo or weekly darbepoetin at a dose of 10 micrograms per kilogram of body weight. Treatment continued until hospital discharge or until the infant reached 35 weeks of gestational age.
When neurodevelopment was assessed at age two using the Bayley-III scale, no significant differences were observed between the darbepoetin and placebo groups. This finding contrasts with earlier studies that had suggested a neuroprotective benefit. However, darbepoetin was associated with significantly increased red blood cell mass, hematocrit, and reticulocyte counts. Interestingly, the trial also reported an unexpected reduction in moderate-to-severe bronchopulmonary dysplasia among infants receiving darbepoetin. These results highlight both inconsistencies with past findings and novel effects that warrant further investigation.
The randomized clinical trial enrolled 650 infants with a mean gestational age of 26.2 weeks. Within 36 hours of birth, participants were assigned to receive either a placebo or weekly darbepoetin at a dose of 10 micrograms per kilogram of body weight. Treatment continued until hospital discharge or until the infant reached 35 weeks of gestational age.
When neurodevelopment was assessed at age two using the Bayley-III scale, no significant differences were observed between the darbepoetin and placebo groups. This finding contrasts with earlier studies that had suggested a neuroprotective benefit. However, darbepoetin was associated with significantly increased red blood cell mass, hematocrit, and reticulocyte counts. Interestingly, the trial also reported an unexpected reduction in moderate-to-severe bronchopulmonary dysplasia among infants receiving darbepoetin. These results highlight both inconsistencies with past findings and novel effects that warrant further investigation.